Dr. Emil Kakkis is Chief Executive Officer, President and Founder of Ultragenyx, a company with four approved therapies for five rare diseases and multiple late-stage clinical programs. He is best known for his work developing novel treatments for rare diseases and working on policy issues affecting rare and ultrarare disease treatment. Dr. Kakkis has received numerous awards including the Life Science Leadership Pantheon award from California Life Sciences, a Lifetime Achievement Award from the National MPS Society, the Roscoe O. Brady Award for innovation from the WORLDSymposium and BIO’s Henri Termeer Visionary Leadership award for his transformative work in rare diseases.